Ireland· IE-PA-EU/1/15/1043/001-002
Nucala 100 mg powder for solution for injection
A other systemic drugs for obstructive airway diseases product containing mepolizumab, registered in Ireland by GlaxoSmithKline Trading Services Limited. The same ATC class is registered in 3 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Mepolizumab is registered in 3 of 19 countries.
Countries holding a registration under ATC R03DX (other systemic drugs for obstructive airway diseases), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 2 of them publish a price we can compare per daily dose
Mepolizumab · ATC R03DX
3 / 19 countries
- Czechiaprice
- Ireland
- Polandprice
The record
At a glance
HPRA (Ireland)- Active substance
- Mepolizumab
- Manufacturer
- GlaxoSmithKline Trading Services Limited
- Country
- Ireland (IE)
- ATC code
- R03DX
- ATC class
- Other systemic drugs for obstructive airway diseases
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/15/1043/001-002
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mepolizumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FranceNUCALA 100 mg, poudre pour solution injectableGLAXOSMITHKLINE TRADING SERVICES (IRLANDE)
- NetherlandsNucala 100 mg poeder voor oplossing voor injectieGlaxoSmithKline Trading Services Limited
- CzechiaNUCALAGlaxoSmithKline Trading Services Limited, Dublin
- ItalyNUCALA*1 flaconcino SC 100 mgGLAXOSMITHKLINE TRAD.SERV.LTD
- FinlandNucalaGlaxoSmithKline Trading Services Limited
- PolandNucalaGlaxoSmithKline Trading Services Limited
- SwedenNucala 100 mg Injektionsvätska, lösning i förfylld injektionspennaGlaxoSmithKline Trading Services Ltd
- United KingdomNucala 100mg powder for solution for injection vialsGlaxoSmithKline UK Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Nucala
- Liechtenstein · Nucala
- Norway · Nucala
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bede5c7c-e58d-4b5c-b36a-75112fd23927 GET /v1/drugs/bede5c7c-e58d-4b5c-b36a-75112fd23927?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder for solution for injection",
"routes": [
"Subcutaneous use"
],
"source": "hpra",
"atc_all": [
"R03DX"
],
"strength": null,
"pa_number": "EU/1/15/1043/001-002",
"substances": [
"Mepolizumab"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "02/12/2015",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about mepolizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.